MPTP-Parkinsonism is accompanied by persistent expression of a Δ-FosB-like protein in dopaminergic pathways

Molecular Brain Research

Volumn 53, Issue 1-2, 1998, Pages 41-52

  Pérez Otaño, Isabel ^a   Mandelzys, Allan ^a   Morgan, James I ^a,b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

AP 1; Dopamine; FosB; Immediate early gene; Mouse; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; IMMEDIATE EARLY GENE; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; ONCOGENE C FOS; ONCOGENE C JUN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGING; ANIMALS; BRAIN; DOPAMINE; FEMALE; GENES, IMMEDIATE-EARLY; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; ORGAN SPECIFICITY; PARKINSON DISEASE, SECONDARY; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION, GENETIC;

ANIMALIA; MURINAE;

EID: 0031933232     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00269-6     Document Type: Article

References (52)

1. Adams J.D. Jr., Odunze I.N. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: could oxidative stress be involved in the brain? Biochem. Pharmacol. 41:1991;1099-1105.
2. Agid Y., Ruberg M., Javoy-Agid F., Hirsch E.C., Raisman-Vozari R., Vyas S., Faucheux B., Michel P., Kastner A., Blanchard V., Damier P., Villares J., Zhang P. Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv. Neurol. 60:1993;148-164.
3. Anglade P., Tsuji S., Javoy-Agid F., Agid Y., Hirsch E.C. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. Ann. Neurol. 37:1995;265-272.
4. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., Leenders K.L. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 52:1995;1183-1190.
5. Bronstein D.M., Ye H., Pennypacker K.E., Hudson P.M., Hong J.S. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat. Mol. Brain Res. 23:1994;191-203.
6. Chen J., Nye H.E., Kelz M.B., Hiroi N., Nakabeppu Y., Hope B.T., Nestler E.J. Regulation of delta FosB and FosB-like proteins by electroconvlusive seizure and cocaine treatments. Mol. Pharmacol. 48:1995;880-889.
7. Date I., Felten D.L., Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519:1990;266-276.
8. De Felipe C., Hunt S.P. The differential control of c-jun expression in regenerating sensory neurons and their associated glial cells. J. Neurosci. 14:1994;2911-2923.
9. Dobrzanski P., Noguchi T., Kovary K., Rizzo C.A., Lazo P.S., Bravo R. Both products of the fosB gene, FosB and its short form, FosB/SF, are transcriptional activators in fibroblasts. Mol. Cell. Biol. 11:1991;5470-5478.
10. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of Δ-FosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 8:1996;365-381.
11. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., Johnson E.M. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J. Cell Biol. 127:1994;1717-1727.
12. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 2501:1990;429-1432.
13. Gerlach M., Riederer P., Przuntek H., Youdim M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208:1991;273-286.
14. Gibb W.R.G., Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 54:1991;388-396.
15. Giovanni A., Sieber B.-A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic toxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257:1991;691-697.
16. Grafe M.R., Forno L.S., Eng L.F. Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's disease. J. Neuropathol. Exp. Neurol. 44:1985;47-59.
17. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. USA. 87:1990;6912-6916.
18. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., Rubin L.L. A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron. 14:1995;927-939.
19. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamineoxidase inhibitors. Nature. 311:1984;467-469.
20. Hope B.T., Kelz M.B., Duman R.S., Nestler E.J. Chronic electroconvulsive seizure (ECS) treatment results in expression of a long-lasting AP-1 complex in brain with altered composition and characteristics. J. Neurosci. 14:1994;4318-4328.
21. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1994;1235-1244.
22. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv. Neurol. 60:1993;140-147.
23. Hyman S.E. Addiction to cocaine and amphetamine. Neuron. 16:1996;901-904.
24. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenyl-tetrahydropyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
25. Jian M., Staines W.A., Iadarola M.J., Robertson G.S. Destruction of the nigrostriatal pathway increases Fos-like immunoreactivity pedominantly in striatopallidal neurons. Mol. Brain Res. 19:1993;156-160.
26. Kasof G., Mandelzys A., Maika S.D., Hammer R.E., Curran T., Morgan J.I. Kainic acid-induced neuronal damage is associated with DNA damage and a unique immediate-early gene response in c-fos-lacZ transgenic rats. J. Neurosci. 15:1995;4238-4249.
27. Langston J.W., Ballard B., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
28. Marsden C.D. Parkinson's disease. Lancet. 335:1990;948-952.
29. Molinar-Rodé R., Smeyne R.J., Curran T., Morgan J.I. Regulation of protooncogene expression in adult and developing lungs. Mol. Cell Biol. 13:1993;3213-3220.
30. Moratalla R., Vickers E.A., Robertson H.A., Cochran B.H., Graybiel A.M. Coordinate expression of c-fos and junB is induced in the rat striatum by cocaine. J. Neurosci. 13:1993;423-433.
31. Moratalla R., Robertson H.A., Graybiel A.M. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J. Neurosci. 12:1992;2609-2622.
32. Morgan J.I., Curran T. Stimulus-transcription coupling in neurons: role of cellular immediate-early genes. Trends Neurosci. 12:1989;459-462.
33. Mumberg D., Lucibello F.C., Schuerman M., Müller R. Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Genes Dev. 5:1991;1212-1223.
34. Nakabeppu Y., Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell. 64:1991;751-759.
35. Pennypacker K.R., Zhang W.Q., Ye H., Hong J.S. Apomorphine induction of AP-1 binding in the rat striatum after dopamine depletion. Mol. Brain Res. 15:1992;151-155.
36. Pennypacker K.R., Hong J.S., McMillian M.K. Implications of prolonged expression of Fos-related antigens. Trends Pharmacol. Sci. 16:1995;317-321.
37. Pennypacker K.R., Thai L., Hong J.S., McMillian M.K. Prolonged expression of AP-1 transcription factors in the rat hippocampus after systemic kainate treatment. J. Neurosci. 14:1994;3998-4006.
38. Rollema H., Kuhr W.G., Kranenbourg G., De Vries J., Van Den Berg C. MPP+ induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J. Pharmacol. Exp. Ther. 245:1988;858-866.
39. Rose S., Nomoto M., Jenner P., Marsden C.D. Transient depletion of nucleus accumbens dopamine content may contribute to the initial akinesia induced by MPTP in commom marmosets. Biochem. Pharmacol. 38:1989;3677-3681.
40. Rosen J.B., Chuang E., Iadarola M.J. Differential induction of Fos protein and a Fos-related antigen following acute and repeated cocaine administration. Mol. Brain Res. 25:1994;168-172.
41. Simmons D.M., Arriza J.L., Swanson L.W. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J. Histotechnol. 12:1989;169-181.
42. Singer T.P., Ramsay R.R. Mechanisms of the neurotoxicity of MPTP. Biochem. Pharmacol. 274:1990;1-8.
43. Sivam S.P. Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brain. Neuropeptides. 18:1991;201-207.
44. Smeyne R.J., Vendrell M., Hayward M., Baker S.J., Miao G.G., Schilling K., Robertson L.M., Curran T., Morgan J.I. Continous c-fos expression precedes programmed cell death in vivo. Nature. 363:1993;166-169.
45. Soares H.D., Curran T., Morgan J.I. Transcription factors as molecular mediators of cell death. Ann. NY Acad. Sci. 15:1994;172-182.
46. Sonnenberg J.L., McGregor-Leon P.F., Curran T., Morgan J.I. Dynamic alterations occur in the level and composition of transcription factor AP-1 complexes after seizure. Neuron. 3:1989;359-365.
47. Sündstrom E., Stromberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57Bl/6 mice. Comparison with three other strains of mice. Brain Res. 405:1987;26-38.
48. Weihmuller F.B., Bruno J.P., Neff N.H., Hadjiconstantionou M. Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse. Eur. J. Pharm. 180:1990;369-372.
49. Wisdom R., Verma I.M. Transformation by Fos proteins requires a C-terminal transactivation domain. Mol. Cell Biol. 13:1993;7429-7438.
50. Yen J., Wisdom R.M., Tratner I., Verma I.M. An alternatively spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins. Proc. Natl. Acad. Sci. USA. 88:1991;5077-5081.
51. 1 receptors. Proc. Natl. Acad. Sci. USA. 88:1991;1291-1295.
52. Zerial M.L., Toschi L., Ryseck R.-P., Schuermann M., Muller R., Bravo R. The product of a novel growth factor activated gene, fosB, interacts with Jun proteins enhancing their DNA binding activity. EMBO J. 8:1989;805-813.